HCPCS code J9302: Ofatumumab injection, per 10 mg2026 Medicare rate & RVUs in New York
J9302 identifies each 10 mg of intravenous ofatumumab administered for chronic lymphocytic leukemia in oncology care.
CMS doesn’t publish an office rate for J9302 in New York.
Medicare allowed amount for participating (non-QP) physicians, before deductible, coinsurance and claim adjustments. Not a patient’s bill or a hospital charge.
Your location
On this page 9 sections
What J9302 covers
J9302 represents ofatumumab, an anti-CD20 monoclonal antibody used in oncology treatment of chronic lymphocytic leukemia (CLL). The oncology formulation is administered by intravenous infusion, typically by clinical staff in a hospital outpatient department or physician office. This is the drug code; it identifies the medication supplied and administered, rather than the infusion service.
CMS assigns J9302 physician fee schedule status E, excluding it from the physician fee schedule. When Medicare covers the drug, payment is under another method; HCPCS pricing identifies it as a Part B drug, generally priced from CMS quarterly Average Sales Price files. Coverage is left to the Medicare contractor’s judgment. One billing unit represents 10 mg of ofatumumab, so the administered dose in milligrams is divided by 10 to determine the units reported.
This summary was written with AI assistance from CMS physician fee schedule data and checked against the CMS billing rules shown here. Rates on this page come directly from CMS files.
Where J9302 pays more and less in New York
The same RVUs, adjusted for each area’s costs. Open a locality for its calculation, history and nearby areas.
| Payment locality | Office | Facility |
|---|---|---|
| Manhattan, NY | Unavailable | Unavailable |
| NYC suburbs and Long Island, NY | Unavailable | Unavailable |
| Poughkeepsie and northern NYC suburbs, NY | Unavailable | Unavailable |
| Queens, NY | Unavailable | Unavailable |
| Rest of New York | Unavailable | Unavailable |
How the J9302 rate is calculated
Each of J9302’s three RVUs is multiplied by a geographic index (GPCI) for the payment locality, added up, and multiplied by the conversion factor. Drag the indexes or enter a ZIP to see what moves the rate.
How the rate is built · J9302
RVUs × geographic indexes × conversion factor
Work0.00
0.00 RVUs× 1.000 GPCI
Practice expense0.00
0.00 RVUs× 1.000 GPCI
Malpractice0.00
0.00 RVUs× 1.000 GPCI
Adjusted RVUs
0.0000
Conversion factor
$33.4009
Medicare rate
$0.00
Every GPCI starts at 1.000, the national rate. Enter a ZIP or drag a slider.
Payment rules and modifiers for J9302
J9302 has no global surgery period, no multiple-procedure, bilateral or assistant-at-surgery adjustment, and no professional/technical split. What changes the payment is where the service happens: the place of service on the claim decides whether Medicare pays the office or the facility rate.
Place of service · J9302
Which rate does Medicare pay?
The POS code on the claim line (CMS-1500 box 24B).
POS 11 · non-facility rate · national
—
J9302 isn’t priced in this setting.
J9302 compared with similar codes
Compare codes · National
J9302 vs J9301 vs J9312: Medicare rates
How to choose
- J9301ObinutuzumabPer 10 mg
- J9301 identifies obinutuzumab, not ofatumumab. Both are anti-CD20 drugs used in CLL care, so select the code for the medication actually administered.
- J9312Rituximab injectionPer 10 mg
- J9312 identifies rituximab, whereas J9302 identifies ofatumumab. They are different drugs even when used for related hematologic treatment needs.
J9302 billing questions
What does one J9302 unit represent?
One unit represents 10 mg of ofatumumab. Divide the administered dose in milligrams by 10 to calculate the units.
Is J9302 the drug or the infusion service?
J9302 reports the ofatumumab drug. The applicable therapeutic infusion administration is reported separately.
How is J9302 different from J9312?
J9302 identifies ofatumumab, while J9312 identifies rituximab. Both are anti-CD20 drugs used in some CLL treatment settings, but they are distinct medications.
How does Medicare treat J9302?
CMS assigns status E, excluding J9302 from the physician fee schedule. When covered, it is a Part B drug generally priced using CMS quarterly ASP files, and coverage is determined by the Medicare contractor.
Should the infusion administration be reported with J9302?
Report the drug and the applicable infusion administration separately. CPT 96413 may describe the initial therapeutic infusion service when its requirements are met.
Where these rates come from
FeeBase calculates base physician payments from CMS work, practice-expense and malpractice RVUs, adjusted by each locality’s geographic indexes and the conversion factor. Services without a published rate are labeled, never given a made-up amount. Amounts are Medicare allowed amounts before claim adjustments: not a patient’s bill or a commercial rate.
CMS RVU26D · effective Oct 1, 2026 through the day before Jan 1, 2027
Fee sheets · Coming soon
Put J9302 and the rest of your codes on one sheet
Your codes at your locality, with payer contracts beside Medicare.
Join the waitlist